THE US Food and Drug
Administration has approved
Remicade (infliximab) to treat
moderately to severely active
ulcerative colitis (UC) in children
older than six years who have had
inadequate response to
conventional therapy.
The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 26 Sep 11
To see the full story, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 Sep 11
